Published as part of the 50 Years SYNTHESIS – Golden Anniversary Issue
Key words C–H activation - annulative coupling - isoquinoline - rhodium catalyst - polyaromatic compounds
Polycyclic aromatic and heteroaromatic compounds have attracted much research interest owing to their substantial and increasing importance as functional organic materials involving light-emitting devices, solar cells, and semiconductors.[1 ] Accordingly, the development of new synthetic methods for such fused-aromatic systems is in high demand.
Transition-metal-catalyzed direct annulative coupling reactions of directing group substituted aromatic substrates with alkynes have been extensively studied in the last few decades because of their high efficiency and operational simplicity.[2 ]
[3 ] In particular, the reactions of this type are powerful synthetic tools for constructing various benzo-fused heteroaromatic molecules through the annulation accompanied by the incorporation of a heteroatom-containing directing group. Under certain circumstances, alkynes may also be multiply annulated onto the aromatic substrates to lead to higher π-extended carbocyclic systems. For example, the dehydrogenative coupling reactions with two equivalents of alkynes under various catalytic conditions including rhodium catalysis have been utilized as straightforward methods for the synthesis of benzo-fused arenes [Scheme [1 ] (a)].[2,4,5 ] These annulative cyclization reactions are potentially useful in exploring novel functional molecules since highly elaborate aromatics can be obtained from readily available starting materials.[6 ]
Scheme 1 Rh-catalyzed annulative coupling reactions
Recently, we have developed the synthesis of 1-substituted isoquinolines[7 ] through coupling using aryl-substituted isoxazoles as the starting substrates as a new repertoire of the rhodium-catalyzed direct transformation chemistry, where the N–O bond of the ring system acts as the internal oxidant [Scheme [1 ] (b)].[8 ] In the course of our continuous investigation into the annulative coupling with alkynes, we have found that 3,5-diarylisoxazoles can undergo cascade oxidative annulation to give rise to the corresponding isoquinoline-conjugated naphtho[1,8-bc ]pyran frameworks with the incorporation of three equivalents of alkyne [Scheme [1 ] (c)]. The naphtho[1,8-bc ]pyran skeleton is involved in various natural and synthetic compounds,[9 ] and their synthesis through the catalytic oxidative annulation on 1-naphthols and related substrates has been achieved by our group[3c ] and the groups of Ackermann,[10 ] Wang,[3h ]
[11 ] and Li.[12 ] In this publication, the scope of this novel catalytic transformation using the isoxazoles and alkynes as the building blocks and the optical properties of the obtained biaryl-type coupling products are described.
As an initial attempt, we examined the reaction of 3,5-diphenylisoxazole (1a ) with excess diphenylacetylene (2a , 3.6 equiv) in the presence of [Cp*Rh(MeCN)3 ][SbF6 ]2 (Cp* = pentamethylcyclopentadienyl) (4.0 mol%) as catalyst and Cu(OAc)2 (4.0 equiv) as oxidant at 100 °C for 18 hours (Table 1, entry 1), and the corresponding 1:3 coupling product 3aa was obtained in 66% NMR yield. Acetate salts of Ag(I) and Mn(III) were not suitable as the oxidants for the present reaction (entries 2 and 3). A number of solvents were then tested (entries 4–7) and the highest yield was achieved using 1,4-dioxane (86%, entry 6). Interestingly, reducing the amount of 2a to 3.1 equivalents resulted in a product yield of 94% (83% after purification) within 9 hours (entry 8). No reaction took place in the absence of any Rh catalyst (entry 9). Throughout the optimization study, a 1:2 coupling product 4aa was sometimes detected in small quantities (<5% yield). This implies that the annulative coupling on the naphthol moiety of 4aa is the last step of the catalytic sequence that leads to 3aa (see discussion below).
Table 1 Optimization Studies for the Coupling of 1a and 2a
a
Entry
2a (equiv)
Oxidant
Solvent
Yieldb (%)
3aa
4aa
1
3.6
Cu(OAc)2
PhCF3
66
n.d.
2
3.6
AgOAc
PhCF3
n.d.
n.d.
3
3.6
Mn(OAc)3 ·2H2 O
PhCF3
8
4
4
3.6
Cu(OAc)2
DCE
62
3
5
3.6
Cu(OAc)2
o -xylene
34
5
6
3.6
Cu(OAc)2
1,4-dioxane
86
n.d.
7
3.6
Cu(OAc)2
DMF
n.d.
n.d.
8c
3.1
Cu(OAc)2
1,4-dioxane
94d
n.d.
9e
3.1
Cu(OAc)2
1,4-dioxane
n.d.
n.d.
a Reaction conditions: 1a (0.2 mmol), 2a (0.62 or 0.72 mmol), oxidant (0.8 mmol), [Cp*Rh(MeCN)3 ][SbF6 ]2 (4.0 mol%), solvent (4.0 mL).
b Determined by NMR analysis; n.d. = not detected.
c Reaction time: 9 h.
d Isolated yield.
e Without the Rh catalyst.
With the reaction conditions of entry 8 in Table 1, we examined the substrate scope of alkynes (Scheme [2 ]). Good to excellent yields were achieved with variously substituted diphenylacetylenes 2 with the exception of 2d and 2g . The lower product yields with 2d and 2g are probably because of their weaker coordinating properties due to the steric bulkiness and the electron-deficient nature, respectively. Of note is that the C–Br linkage in 2h remained intact during the reaction. An aliphatic alkyne, oct-4-yne (2i ) was also applicable to furnish the corresponding product in 63% yield. No productive results were obtained with silyl- or carbonyl-substituted alkynes (not shown).
Scheme 2 Substrate scope for alkynes. a Reaction at 120 °C.
We then carried out the reactions of various 3,5-diarylisoxazoles 1b –n with diphenylacetylene (2a ) (Scheme [3 ]). A variety of substituents can be installed onto the naphtho[1,8-bc ]pyran subunit by using isoxazoles 1b –g with different substituents on the 5-aryl group. It is noteworthy that the reaction of 1g resulted in the selective formation of 3ga in which the methyl group is placed at the C4 position of the ring system. This peculiar regioselectivity seems to be achieved as the second annulation takes place at the sterically more accessible site (see discussion below). Additionally, the catalytic system can be utilized for the construction of a thienochromene framework to give 3ha as a single isomer albeit with a low yield. The structures of 3ga and 3ha were unambiguously determined by X-ray crystallography.[13 ] Apparently, functionality on the 3-aryl group of the isoxazoles falls into the isoquinoline subunit. Thus, the 1:3 coupling products 3ia –ma were obtained in high yields with use of isoxazoles 1i –m having a substituent on the 3-aryl group. No significant drop of the product yield was observed even in the presence of an ortho -methyl substituent (3ma ). A thienopyridine moiety was also constructed albeit with low yield (3na ). When isoxazoles 1o and 1p were employed, the corresponding 1:2 coupling products 4oa and 4pa were formed selectively. This is apparently due to the fact that no Csp2 –H bond for the third annulation is available in the products (Scheme [4 ]).
Scheme 3 Substrate scope for isoxazoles. a Reaction at 130 °C for 24 h.
Scheme 4 Annulative coupling with two equivalents of alkynes
A proposed catalytic cycle for the reaction of 1a with 2 is illustrated in Scheme [5 ]. The reaction is initiated by coordination-assisted C–H bond activation to form a five-membered rhodacycle complex A . Then, alkyne insertion and subsequent formal SN -type reaction[8g ]
[14 ] onto the nearby N–O bond gives a Rh alkoxide species C , which is in equilibrium with a carbon-enolate complex D . From this stage, oxidative annulation undergoes with incorporating the second alkyne molecule to construct the naphthol moiety.
Scheme 5 Proposed reaction mechanism
According to the following control experiment, it is assumed that the catalytic Rh species may be liberated only after the second annulative coupling. We adopted α-(2-pyridyl)acetophenone (5 ), which is structurally analogous to the 1:1 coupling product, to the optimal reaction conditions; however, no C–C bond forming reaction was triggered (Scheme [6 ], upper). Finally, another oxidative coupling proceeded with the third alkyne molecule to furnish the 1:3 coupling products 3 . This step was confirmed separately by the reaction of 4aa with 2a affording the product 3aa in a high yield (Scheme [6 ], lower). In total, four C–C bonds, one C–N bond, and one C–O bond are formed in a one-shot manner.
Scheme 6 Control experiments
It has been reported that a series of naphtho[1,8-bc ]pyran derivatives exhibit relatively strong fluorescence even in their solid state.[3c ]
[9c ] Consequently, we investigated the optical properties of the present coupling products (Figure [1 ]). When excited at 342 nm, 3aa emitted a green fluorescence with a broad spectral width ranging from 450 nm to 600 nm in chloroform solution [Figure [1 ] (b)]. No obvious bathochromic shift was observed in the solid state measurement and the quantum efficiency was comparable: 0.15 for the CHCl3 solution and 0.11 for the powder [Figure [1 ] (d) and Table S1].
Interestingly, 3aa showed a characteristic spectral change in response to the formation of an isoquinolinium salt. We first prepared a hydrochloric salt of 3aa (3aa ·HCl) and measured its spectra. The color changed from light yellow to deep orange with expansion of the absorption edge up to 600 nm [Figure [1 ] (a) and (c)]. On the other hand, the emission intensity was considerably decreased in the solution and eventually quenched in the solid state [Figure [1 ] (d)]. This difference between the solution and the solid is due to the fact that the salt can partly dissociate into free 3aa and HCl in chloroform. Indeed, more obvious spectral change was observed when excess HCl (1.0 mol/L in Et2 O) was added [Figure [1 ] (a) and (b)] to the solution. The reversibility of this event is realized by the sequential addition of HCl and Et3 N. We also synthesized an N-methylated isoquinolinium salt 3aa ·MeOTf as a reference, and as expected, similar spectra to those of 3aa in the presence of the excess HCl were obtained in the solution since the dissociation of the CH3 –N bond is not possible in this case.
Figure 1 (a) UV-vis absorption and (b) fluorescence spectra of 3aa (black), 3aa ·HCl (orange), 3aa ·HCl + 10 equiv of HCl (blue), and 3aa ·MeOTf (gray) in CHCl3 solution (5.0 × 10–5 mol/L); the fluorescence spectra of 3aa ·HCl + 10 equiv of HCl and 3aa ·MeOTf overlap close to the baseline. (c) UV-vis absorption and (d) fluorescence spectra of 3aa (black), 3aa ·HCl (orange), and 3aa ·MeOTf (gray) in solid state.
Substituents on the naphthopyran or isoquinoline motif did not largely affect the luminescence property, and the tested molecules (3ae , 3af , 3ag , 3ca , 3da , 3ea , and 3ja ) recorded similar fluorescence spectra within 20 nm shift of the peak top. In contrast, the compound 3ai which is derived from an aliphatic alkyne showed blue-green emission with the peak top at around 470 nm (Figure [2 ]).
Figure 2 Normalized fluorescence spectra of 3ae (blue), 3af (orange), 3ag (gray), 3ai (red), 3ca (yellow), 3da (purple), 3ea (navy), and 3ja (green) at room temperature. (a) Spectra in CHCl3 solution (left, 5.0 × 10–6 mol/L). (b) Spectra in solid state (right).
Additionally, we looked into the potential axial chirality of the coupling products. As a representative example, compound 3ag can be separated into a pair of enantiomers in a chiral HPLC analysis (see the Supporting Information). Further studies on their chiroptical properties are underway in our group.
In summary, we have developed a rhodium-catalyzed cascade annulative coupling reaction of 3,5-diarylisoxazoles with alkynes. In this catalytic system, three equivalents of alkynes are consolidated and isoquinoline-conjugated naphtho[1,8-bc ]pyran frameworks are efficiently constructed by a single manipulation. The starting isoxazole derivatives are readily available and can be stored without any special treatments. The coupling products exhibit fluorescence in both the solution and solid state, and additionally, its turn-off/on is reversibly achievable by treatment with an acid and a base.
All manipulations were performed under N2 using standard Schlenk techniques unless otherwise noted. DMF and 1,4-dioxane were dried and deoxygenated by a Glass Counter Solvent Dispending System (Nikko Hansen & Co., Ltd.). PhCF3 , DCE, and o -xylene were distilled from CaH2 and stored with molecular sieves 4Å. CH2 Cl2 was degassed with N2 bubbling and dried with molecular sieves 4Å. THF (stabilizer free) was purchased from Wako Pure Chemical Industries as dehydrated solvent and used without purification. Silica gel column chromatography was performed using Wakosil® C-200 (64–210 μm) or Kanto Chemical 60N (40–100μm). 3,5-Diphenylisoxazole (1a ) was synthesized according to the literature procedure.[15 ] The other isoxazoles were synthesized by the copper-catalyzed cycloaddition of oxime chlorides with terminal alkynes according to the literature procedure.[16 ] Alkynes 2b –h ,[17 ] rhodium complexes,[3b ]
[18 ] and α-(2-pyridyl)acetophenone (5 )[19 ] were synthesized according to the literature. All other reagents were commercially available and used without further purification.
NMR spectra were measured at 400 MHz (1 H NMR), at 100 MHz (13 C NMR), and at 376 MHz (19 F NMR) in 5 mm NMR tubes. 1 H NMR chemical shifts were reported relative to the resonance of TMS (δ = 0.00) or the residual solvent signals at δ = 7.26 for CDCl3 . 13 C NMR chemical shifts were reported relative to the residual solvent signals at δ = 77.2 for CDCl3 . Melting points were measured with Mettler Toledo MP90. HRMS were recorded by APCI-TOF. GC analyses were carried out with Shimadzu GC8APF equipped with a silicon OV-17 column (2.6 mm × 1.5 m). GC-MS spectra were recorded on Shimadzu GCMS-QP2010 SE with a CBP-1 column (0.5 mm × 25 m). Preparative gel permeation chromatography (GPC) was conducted with Showa Denko H-2001/H-2002 (eluent: CHCl3 ) or YMC T2000 (eluent: EtOAc) column. Absorption and fluorescence spectra were recorded on JASCO V-750 and JASCO FP8500 spectrometers. Quantum efficiency was determined using an integration sphere system.
Isoxazole Derivatives 1;[15 ]
[16 ]
[20 ] General Procedure
Isoxazole Derivatives 1;[15 ]
[16 ]
[20 ] General Procedure
Oxime chloride (1.0 mmol) and terminal alkyne (1.0 mmol) were dissolved in H2 O/t -BuOH (1:1, 6.0 mL) under an N2 atmosphere. To the solution, sodium ascorbate (0.1 mmol, 1.0 mol/L in water), CuSO4 ·5H2 O (0.02 mmol in 0.10 mL of water), and NaHCO3 (4.33 mmol, 4.33 equiv) were added at r.t. The mixture was stirred overnight and then it was poured into EtOAc; the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried (Na2 SO4 ), and concentrated in vacuo. Unless otherwise noted, the residue was subjected to column chromatography (silica gel, hexane/EtOAc 9:1), and further purification was conducted by recrystallization (hexane layered over EtOAc solution).
3,5-Diphenylisoxazole (1a)[20d ]
3,5-Diphenylisoxazole (1a)[20d ]
White solid; yield: 281 mg (64%).
1 H NMR (400 MHz, CDCl3 ): δ = 6.84 (s, 1 H), 7.43–7.52 (m, 6 H), 7.83–7.89 (m, 4 H).
13 C NMR (100 MHz, CDCl3 ): δ = 97.5, 125.9, 126.8, 127.5, 129.0, 129.0, 129.2, 130.1, 130.3, 163.0, 170.4.
3-Phenyl-5-(p -tolyl)isoxazole (1b)[20d ]
3-Phenyl-5-(p -tolyl)isoxazole (1b)[20d ]
White solid; yield: 98 mg (42%).
1 H NMR (400 MHz, CDCl3 ): δ = 2.42 (s, 3 H), 6.78 (s, 1 H), 7.29–7.31 (m, 2 H), 7.45–7.50 (m, 3 H), 7.73–7.75 (m, 2 H), 7.86–7.88 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.5, 96.9, 124.8, 125.8, 126.8, 128.9, 129.3, 129.7, 129.9, 140.5, 162.9, 170.6.
5-(4-tert -Butylphenyl)-3-phenylisoxazole (1c)
5-(4-tert -Butylphenyl)-3-phenylisoxazole (1c)
Purified by column chromatography (hexane/EtOAc 15:1); white solid; yield (2.0-mmol scale): 276 mg (50%); mp 95–97 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 1.36 (s, 9 H), 6.79 (s, 1 H), 7.46–7.52 (m, 5 H), 7.76–7.79 (m, 2 H), 7.86–7.88 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 31.2, 34.9, 97.0, 124.8, 125.7, 126.0, 126.8, 128.9, 129.3, 130.0, 153.7, 162.9, 170.6.
HRMS (APCI): m /z [M + H]+ calcd for C19 H20 NO: 278.1539; found: 278.1538.
5-(4-Methoxyphenyl)-3-phenylisoxazole (1d)[20e ]
5-(4-Methoxyphenyl)-3-phenylisoxazole (1d)[20e ]
White solid; yield: 122 mg (48%).
1 H NMR (400 MHz, CDCl3 ): δ = 3.88 (s, 3 H), 6.71 (s, 1 H), 6.99–7.01 (m, 2 H), 7.45–7.51 (m, 3 H), 7.77–7.80 (m, 2 H), 7.84–7.88 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 55.4, 96.1, 114.4, 120.4, 126.8, 127.5, 128.9, 129.3, 129.9, 161.2, 163.0, 170.4.
3-Phenyl-5-[4-(trifluoromethyl)phenyl]isoxazole (1e)[20c ]
3-Phenyl-5-[4-(trifluoromethyl)phenyl]isoxazole (1e)[20c ]
White solid; yield: 130 mg (45%).
1 H NMR (400 MHz, CDCl3 ): δ = 6.94 (s, 1 H), 7.48–7.52 (m, 3 H), 7.76 (d, J = 8.2 Hz, 2 H), 7.87–7.89 (m, 2 H), 7.96–7.98 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 98.9, 123.7 (q, J = 271.0 Hz), 126.1 (q, J = 3.8 Hz), 126.8, 128.8, 128.8, 129.0, 130.3, 130.6, 131.9 (q, J = 32.7 Hz), 163.2, 168.8.
19 F NMR (376 MHz, CDCl3 ): δ = –62.9.
5-(4-Bromophenyl)-3-phenylisoxazole (1f)[20d ]
5-(4-Bromophenyl)-3-phenylisoxazole (1f)[20d ]
White solid; yield: 112 mg (37%).
1 H NMR (400 MHz, CDCl3 ): δ = 6.84 (s, 1 H), 7.48–7.49 (m, 3 H), 7.62–7.64 (m, 2 H), 7.70–7.72 (m, 2 H), 7.85–7.87 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 97.9, 124.6, 126.4, 126.8, 127.3, 128.9, 129.0, 130.1, 132.3, 163.1, 169.3.
3-Phenyl-5-(m -tolyl)isoxazole (1g)[20c ]
3-Phenyl-5-(m -tolyl)isoxazole (1g)[20c ]
Purified by column chromatography and GPC (EtOAc); white solid; yield: 80 mg (34%).
1 H NMR (400 MHz, CDCl3 ): δ = 2.43 (s, 3 H), 6.81 (m, 1 H), 7.25–7.27 (m, 1 H), 7.35–7.39 (m, 1 H), 7.45–7.50 (m, 3 H), 7.63–7.66 (m, 2 H), 7.86–7.88 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.5, 97.4, 123.0, 126.4, 126.8, 127.4, 128.9, 129.2, 130.0, 131.0, 138.8, 163.0, 170.6.
3-Phenyl-5-(thiophen-3-yl)isoxazole (1h)
3-Phenyl-5-(thiophen-3-yl)isoxazole (1h)
White solid; yield (2.0-mmol scale): 116 mg (25%); mp 120–122 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.69 (s, 1 H), 7.43–7.50 (m, 5 H), 7.83–7.87 (m, 3 H).
13 C NMR (100 MHz, CDCl3 ): δ = 97.3, 124.3, 125.4, 126.8, 127.1, 128.9 (2 C), 129.1, 130.0, 162.9, 166.6.
HRMS (APCI): m /z [M + H]+ calcd for C13 H10 NOS: 228.0478; found: 228.0467.
5-Phenyl-3-(p -tolyl)isoxazole (1i)[20d ]
5-Phenyl-3-(p -tolyl)isoxazole (1i)[20d ]
White solid; yield (3.0-mmol scale): 188 mg (27%).
1 H NMR (400 MHz, CDCl3 ): δ = 2.42 (s, 3H), 6.81 (s, 1 H), 7.28–7.30 (m, 2 H), 7.43–7.52 (m, 3 H), 7.75–7.78 (m, 2 H), 7.82–7.85 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.5, 97.4, 125.8, 126.3, 126.7, 127.6, 129.0, 129.6 (2 C), 130.2, 162.9, 170.2.
3-(4-Methoxyphenyl)-5-phenylisoxazole (1j)[20e ]
3-(4-Methoxyphenyl)-5-phenylisoxazole (1j)[20e ]
White solid; yield (3.0-mmol scale): 150 mg (20%).
1 H NMR (400 MHz, CDCl3 ): δ = 3.87 (s, 3 H), 6.78 (s, 1 H), 6.99–7.01 (m, 2 H), 7.43–7.51 (m, 3 H), 7.79–7.85 (m, 4 H).
13 C NMR (100 MHz, CDCl3 ): δ = 55.4, 97.3, 114.3, 121.7, 125.8, 127.6, 128.2, 129.0, 130.2, 161.0, 162.6, 170.2.
5-Phenyl-3-[4-(trifluoromethyl)phenyl]isoxazole (1k)[20f ]
5-Phenyl-3-[4-(trifluoromethyl)phenyl]isoxazole (1k)[20f ]
White solid; yield: 59 mg (20%).
1 H NMR (400 MHz, CDCl3 ): δ = 6.87 (s, 1 H), 7.48–7.54 (m, 3 H), 7.75 (d, J = 8.1 Hz, 2 H), 7.85–7.87 (m, 2 H), 7.99–8.01 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 97.4, 123.9 (q, J = 270.7 Hz), 125.9, 126.0 (q, J = 3.7 Hz), 126.0, 127.2, 129.1, 130.5, 131.4 (q, J = 32.4 Hz), 132.6, 161.9, 171.1.
19 F NMR (376 MHz, CDCl3 ): δ = –62.8.
5-Phenyl-3-(m -tolyl)isoxazole (1l)[20b ]
5-Phenyl-3-(m -tolyl)isoxazole (1l)[20b ]
Purified by column chromatography and GPC (CHCl3 ); white solid; yield (3.0-mmol scale): 344 mg (49%).
1 H NMR (400 MHz, CDCl3 ): δ = 2.44 (s, 3 H), 6.83 (s, 1 H), 7.29–7.30 (m, 1 H), 7.30–7.34 (m, 1 H), 7.45–7.52 (m, 3 H), 7.65–7.67 (m, 1 H), 7.70–7.71 (m, 1 H), 7.84–7.86 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.4, 97.6, 124.0, 125.9, 127.4, 127.5, 128.8, 129.0 (2 C), 130.2, 130.8, 138.7, 163.1, 170.3.
5-Phenyl-3-(o -tolyl)isoxazole (1m)[20a ]
5-Phenyl-3-(o -tolyl)isoxazole (1m)[20a ]
Purified by column chromatography and GPC (EtOAc); yellow oil; yield (2.5-mmol scale): 258 mg (44%).
1 H NMR (400 MHz, CDCl3 ): δ = 2.53 (s, 3 H), 6.70 (s, 1 H), 7.27–7.38 (m, 3 H), 7.43–7.51 (m, 3 H), 7.55–7.57 (m, 1 H), 7.83–7.86 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.1, 100.2, 125.9, 126.0, 127.5, 128.9, 129.0, 129.5, 129.5, 130.2, 131.1, 136.9, 163.7, 169.6.
5-Phenyl-3-(thiophen-2-yl)isoxazole (1n)[20g ]
5-Phenyl-3-(thiophen-2-yl)isoxazole (1n)[20g ]
White solid; yield (3.0-mmol scale): 141 mg (21%).
1 H NMR (400 MHz, CDCl3 ): δ = 6.76 (s, 1 H), 7.13–7.15 (m, 1 H), 7.43–7.53 (m, 5 H), 7.81–7.83 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 97.5, 125.9, 127.2, 127.4, 127.7, 127.7, 129.0, 130.4, 130.9, 158.2, 170.4.
3-Phenyl-5-(thiophen-2-yl)isoxazole (1o)[20c ]
3-Phenyl-5-(thiophen-2-yl)isoxazole (1o)[20c ]
Purified by column chromatography (hexane/EtOAc 10:1); white solid; yield: 97 mg (43%).
1 H NMR (400 MHz, CDCl3 ): δ = 6.69 (s, 1 H), 7.13–7.15 (m, 1 H), 7.45–7.47 (m, 4 H), 7.55–7.56 (m, 1 H), 7.83–7.86 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 97.3, 126.9, 127.1, 128.0, 128.1, 128.7, 128.9, 129.3, 130.1, 163.0, 164.4.
3-Phenyl-5-(o -tolyl)isoxazole (1p)[20c ]
3-Phenyl-5-(o -tolyl)isoxazole (1p)[20c ]
Purified by column chromatography and GPC (CHCl3 ); yellow oil; yield: 93 mg (39%).
1 H NMR (400 MHz, CDCl3 ): δ = 2.57 (s, 3 H), 6.72 (s, 1 H), 7.30–7.39 (m, 3 H), 7.46–7.51 (m, 3 H), 7.75–7.78 (m, 1 H), 7.87–7.90 (m, 2 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.5, 100.6, 126.3, 126.8, 127.1, 128.6, 128.9, 129.3, 130.0, 130.1, 131.4, 136.3, 162.6, 170.6.
Rh-Catalyzed Annulative Coupling (Scheme [2 ] and Scheme [3 ]); General Procedure
Rh-Catalyzed Annulative Coupling (Scheme [2 ] and Scheme [3 ]); General Procedure
A glass tube equipped with a magnetic stir bar was charged with isoxazole 1 (0.2 mmol), alkyne 2 (0.62 mmol, 3.1 equiv), [Cp*Rh(MeCN)3 ](SbF6 )2 (0.008 mmol, 4.0 mol%), and Cu(OAc)2 (0.8 mmol, 4.0 equiv). The tube was evacuated and backfilled with N2 (3 ×) followed by addition of 1,4-dioxane (4.0 mL) via syringe. The resulting mixture was heated at 100 °C for 12 h. After cooling to r.t., the mixture was poured into water and extracted with EtOAc (3 ×). The combined organic extracts were washed with brine, dried (Na2 SO4 ), and concentrated under reduced pressure. The residue was subjected to column chromatography (silica gel) to afford the corresponding product. Further purification was performed by GPC if required.
Note: the coupling products 3 exhibit broadened and split peaks in NMR spectra owing to the presence of rotamers, and the following data are reported as appeared in the spectra.
3,4-Diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3aa)
3,4-Diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3aa)
Purified by column chromatography (hexane/EtOAc 5:1); yellow solid; yield: 125 mg (83%); mp 167–169 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.54 (dd, J = 1.0, 7.1 Hz, 1 H), 6.70–6.72 (m, 4 H), 6.80–6.89 (m, 4 H), 6.97–7.03 (m, 2 H), 7.11 (s, 5 H), 7.13–7.33 (m, 12 H), 7.34–7.40 (m, 5 H), 7.48–7.53 (m, 2 H), 7.55–7.58 (m, 1 H), 8.16–8.17 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 116.4, 117.4, 118.7, 121.9, 123.1, 125.7, 126.4, 126.5, 126.7, 127.1, 127.2, 127.3, 127.4, 127.5, 127.7, 127.8, 127.9, 128.0, 128.0, 128.2, 128.4, 128.5, 129.3, 129.4, 129.7, 130.0, 130.3, 130.9, 131.0, 131.2, 131.4, 131.5, 131.6, 131.8, 132.3, 133.7, 133.9, 135.6, 136.1, 137.5, 139.1, 139.7, 140.7, 141.1, 148.7, 149.7, 149.9, 156.9.
HRMS (APCI): m /z [M + H]+ calcd for C57 H38 NO: 752.2948; found: 752.2946.
2-(3,4-Diphenylisoquinolin-1-yl)-3,4-diphenylnaphthalen-1-ol (4aa)
2-(3,4-Diphenylisoquinolin-1-yl)-3,4-diphenylnaphthalen-1-ol (4aa)
Purified by column chromatography (hexane/EtOAc 10:1) and GPC; yellow solid; crystals suitable for X-ray measurement were obtained by pentane vapor diffusion into the EtOAc solution; mp 258–260 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.55–6.70 (m, 3 H), 6.76–6.85 (m, 1 H), 6.90–6.92 (m, 2 H), 7.01–7.02 (m, 1 H), 7.07–7.10 (m, 3 H), 7.15–7.23 (m, 5 H), 7.26–7.47 (m, 8 H), 7.50–7.56 (m, 2 H), 7.78 (d, J = 8.1 Hz, 1 H), 8.48–8.50 (m, 1 H), 9.20 (br, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 118.6, 123.0, 124.8, 125.2, 125.3, 125.5, 126.3, 126.3, 126.4, 126.5, 126.6, 127.1, 127.2, 127.4, 127.5, 127.8, 127.9, 128.5, 130.2, 130.2, 131.1, 131.2, 131.4, 131.7, 132.1, 133.8, 136.5, 137.1, 138.6, 139.4, 139.8, 140.2, 148.8, 150.7, 157.9.
HRMS (APCI): m /z [M + H]+ calcd for C43 H30 NO: 576.2322; found: 576.2321.
1-(2,3,7,8-Tetra-p -tolylbenzo[de ]chromen-9-yl)-3,4-di-p -tolylisoquinoline (3ab)
1-(2,3,7,8-Tetra-p -tolylbenzo[de ]chromen-9-yl)-3,4-di-p -tolylisoquinoline (3ab)
Purified by column chromatography (hexane/EtOAc 5:1) and GPC; yellow solid; yield: 132 mg (79%); mp 180–182 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 2.06 (s, 3 H), 2.15 (s, 3 H), 2.25 (s, 3 H), 2.31 (s, 3 H), 2.39 (s, 6 H), 6.42–6.60 (m, 4 H), 6.61–6.82 (m, 4 H), 6.84–6.96 (m, 2 H), 7.02–7.21 (m, 16 H), 7.43–7.50 (m, 2 H), 7.56 (d, J = 7.7 Hz, 1 H), 8.09–8.12 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.0, 21.2, 21.2, 21.3, 21.4, 21.4, 116.0, 116.7, 118.8, 121.7, 122.9, 125.7, 126.2, 127.2, 127.3, 127.6, 127.9, 128.0, 128.1, 128.4, 128.6, 128. 7, 129.0, 129.1, 129.5, 130.0, 130.2, 130.7, 130.8, 131.0, 131.0, 131.2, 131.40, 131.4, 132.7, 132.8, 134.0, 134.8, 134.8, 135.6, 136.3, 136.3, 136.8, 137.2, 137.9, 138.4, 140.6, 148.5, 149.6, 149.8, 157.0.
HRMS (APCI): m /z [M + H]+ calcd for C63 H50 NO: 836.3887; found: 836.3884.
1-(2,3,7,8-Tetra-m -tolylbenzo[de ]chromen-9-yl)-3,4-di-m -tolylisoquinoline (3ac)
1-(2,3,7,8-Tetra-m -tolylbenzo[de ]chromen-9-yl)-3,4-di-m -tolylisoquinoline (3ac)
Purified by column chromatography (hexane/EtOAc 10:1); yellow solid; yield: 142 mg (85%); mp 150–152 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 1.66–2.44 (m, 18 H), 6.40–6.76 (m, 8 H), 6.80–7.18 (m, 15 H), 7.20–7.40 (m, 3 H), 7.54–7.59 (m, 3 H), 8.19 (br, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.3, 21.3, 21.4, 21.4, 21.5, 116.2, 117.4, 118.6, 121.7, 123.1, 125.9, 125.9, 126.3, 126.4, 126.9, 127.0, 127.4, 127.6, 127.7, 128.1, 128.2, 128.3, 128.4, 128.6, 128.7, 129.0, 129.1, 129.3, 129.6, 131.1, 131.2, 131.6, 131.7, 132.1, 132.2, 132.3, 132.5, 133.6, 133.9, 135.6, 135.7, 136.1, 136.1, 136.8, 137.2, 137.6, 137.9, 138.8, 138.9, 139.2, 139.6, 140.8, 141.0, 148.4, 149.6, 149.7, 157.1.
HRMS (APCI): m /z [M + H]+ calcd for C63 H50 NO: 836.3887; found: 836.3878.
1-(2,3,7,8-Tetra-o -tolylbenzo[de ]chromen-9-yl)-3,4-di-o -tolylisoquinoline (3ad)
1-(2,3,7,8-Tetra-o -tolylbenzo[de ]chromen-9-yl)-3,4-di-o -tolylisoquinoline (3ad)
Purified by column chromatography (hexane/EtOAc 10:1) and GPC; yellow solid; yield: 48 mg (29%); crystals suitable for X-ray measurement are obtained from MeOH solution layered with hexane; mp 187–189 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 1.44–2.42 (m, 18 H), 6.30–6.42 (m, 1 H), 6.57–6.70 (m, 1 H), 6.70–7.16 (m, 15 H), 7.16–7.21 (m, 10 H), 7.35–7.50 (m, 2 H), 7.99–8.12 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 19.2, 19.2, 19.3, 19.4, 19.4, 19.6, 19.7, 19.7, 19.8, 19.9, 19.9, 20.1, 20.1, 20.2, 20.3, 20.6, 20.6, 20.9, 20.9, 21.3, 115.7, 115.8, 115.9, 117.1, 117.6, 117.8, 118.0, 118.6, 119.1, 119.2, 122.0, 122.1, 122.7, 122.8, 122.9, 123.4, 124.3, 124.5, 124.6, 124.9, 125.2, 125.3, 125.5, 125.8, 125.9, 126.1, 126.2, 126.3, 126.4, 126.8, 126.9, 126.9, 127.0, 127.0, 127.1, 127.4, 127.6, 127.7, 127.8, 127.8, 128.2, 128.3, 128.4, 128.7, 128.8, 129.2, 129.5, 129.5, 129.6, 129.6, 129.7, 129.7, 129.8, 129.9, 130.1, 130.2, 130.4, 130.7, 130.7, 130.9, 131.0, 131.3, 131.5, 131.8, 132.0, 132.1, 132.7, 132.9, 133.0, 133.2, 133.3, 133.5, 133.6, 133.7, 134.2, 134.7, 134.8, 135.6, 135.6, 136.1, 136.2, 136.4, 136.6, 136.7, 136.9, 136.9, 136.9, 137.1, 137.2, 137.3, 137.4, 137.5, 137.6, 137.8, 138.0, 138.1, 138.6, 140.0, 140.4, 140.5, 140.8, 149.7, 150.0, 151.0, 151.2, 151.3, 155.9.
HRMS (APCI): m /z [M + H]+ calcd for C63 H50 NO: 836.3887; found: 836.3882.
3,4-Bis(4-tert -butylphenyl)-1-[2,3,7,8-tetrakis(4-tert -butylphenyl)benzo[de ]chromen-9-yl]isoquinoline (3ae)
3,4-Bis(4-tert -butylphenyl)-1-[2,3,7,8-tetrakis(4-tert -butylphenyl)benzo[de ]chromen-9-yl]isoquinoline (3ae)
Purified by column chromatography (hexane/EtOAc 20:1) and GPC; yellow solid; yield: 165 mg (76%); mp 205–207 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 1.08 (s, 9 H), 1.17 (s, 9 H), 1.21 (s, 9 H), 1.27 (s, 9 H), 1.34 (s, 9 H), 1.36 (s, 9 H), 6.50–6.52 (m, 1 H), 6.58 (d, J = 8.6 Hz, 2 H), 6.80–6.82 (m, 3 H), 6.95 (d, J = 8.5 Hz, 2 H), 7.04–7.07 (m, 3 H), 7.10–7.24 (m, 9 H), 7.28–7.32 (m, 3 H), 7.41 (m, 3 H), 7.46–7.54 (m, 2 H), 7.62–7.64 (m, 1 H), 8.18–8.20 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 31.1, 31.2, 31.3, 31.4, 31.4, 31.5, 34.1, 34.3, 34.4, 34.6, 34.7, 116.0, 116.8, 118.9, 121.7, 122.9, 123.1, 124.0, 124.1, 124.5, 124.5, 125.8, 126.1, 126.2, 127.4, 127.7, 1278.0, 128.2, 129.0, 129.4, 129.9, 130.4, 130.7, 130.8, 130.9, 131.0, 131.1, 131.1, 131.3, 132.8, 133.8, 134.7, 136.3, 136.3, 137.0, 138.4, 141.0, 148.0, 148.4, 148.9, 149.1, 149.7, 149.8, 149.9, 150.8, 157.0.
HRMS (APCI): m /z [M + H]+ calcd for C81 H86 NO: 1088.6704; found: 1088.6674.
3,4-Bis(4-methoxyphenyl)-1-[2,3,7,8-tetrakis(4-methoxyphenyl)benzo[de ]chromen-9-yl]isoquinoline (3af)
3,4-Bis(4-methoxyphenyl)-1-[2,3,7,8-tetrakis(4-methoxyphenyl)benzo[de ]chromen-9-yl]isoquinoline (3af)
Purified by column chromatography (hexane/EtOAc 2:1) and GPC; yellow solid; yield: 139 mg (75%); mp 187–189 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 3.57 (d, J = 5.8 Hz, 3 H), 3.64 (d, J = 5.8 Hz, 3 H), 3.73 (d, J = 5.8 Hz, 3 H), 3.78 (d, J = 5.8 Hz, 3 H), 3.83–3.84 (m, 6 H), 6.25 (br, 1 H), 6.33–6.37 (m, 2 H), 6.46–6.55 (m, 2 H), 6.55–6.65 (m, 2 H), 6.65–6.72 (m, 2 H), 6.77–6.84 (m, 3 H), 6.84–7.00 (m, 4 H), 7.00–7.20 (m, 9 H), 7.26–7.34 (m, 1 H), 7.42–7.51 (m, 2 H), 7.57–7.60 (m, 1 H), 8.06–8.09 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 55.0, 55.1, 55.2, 55.3, 112.1, 112.6, 112.9, 113.4, 113.6, 113.8, 114.8, 115.6, 115.8, 118.9, 121.7, 122.6, 125.7, 126.2, 126.4, 127.2, 127.5, 128.1, 128.5, 129.6, 130.0, 130.6, 131.6, 131.7, 132.0, 132.2, 132.3, 132.4, 132.5, 132.6, 132.9, 133.9, 134.2, 136.5, 140.4, 148.5, 149.6, 149.6, 157.0, 157.3, 157.9, 158.4, 158.6, 158.9, 159.0.
HRMS (APCI): m /z [M + H]+ calcd for C63 H50 NO7 : 932.3582; found: 932.3563.
1-{2,3,7,8-Tetrakis[4-(trifluoromethyl)phenyl]benzo[de ]chromen-9-yl}-3,4-bis[4-(trifluoromethyl)phenyl]isoquinoline (3ag)
1-{2,3,7,8-Tetrakis[4-(trifluoromethyl)phenyl]benzo[de ]chromen-9-yl}-3,4-bis[4-(trifluoromethyl)phenyl]isoquinoline (3ag)
Purified by column chromatography (hexane/EtOAc 5:1); yellow solid; yield: 107 mg (46%); mp 341–343 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.58–6.60 (m, 1 H), 6.72 (d, J = 8.2 Hz, 2 H), 6.78 (d, J = 7.8 Hz, 1 H), 6.97–7.04 (m, 4 H), 7.11–7.13 (m, 2 H), 7.18–7.22 (m, 2 H), 7.28–7.42 (m, 6 H), 7.47–7.62 (m, 6 H), 7.67–7.76 (m, 5 H), 8.28–8.30 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 117.6, 118.0, 118.3, 121.9, 122.2, 122.5, 122.7, 123.7, 124.5, 124.6, 124.7, 124.7, 124.9, 125.3, 125.4, 125.8, 125.9, 126.5, 126.8, 127.2, 127.5, 127.9, 128.4, 128.6, 129.0, 129.2, 129.3, 129.6, 129.8, 129.9, 130.2, 130.4, 130.5, 130.6, 130.9, 131.1, 131.4, 131.5, 131.6, 131.7, 132.1, 133.7, 135.6, 136.3, 138.5, 139.6, 140.3, 142.0, 142.9, 143.6, 147.9, 148.7, 149.8, 156.7.
19 F NMR (376 MHz, CDCl3 ): δ = –62.54, –62.56, –62.61, –62.65, –62.69, –69.92.
HRMS (APCI): m /z [M + H]+ calcd for C63 H32 F18 NO: 1160.2191; found: 1160.2174.
3,4-Bis(4-bromophenyl)-1-[2,3,7,8-tetrakis(4-bromophenyl)benzo[de ]chromen-9-yl]isoquinoline (3ah)
3,4-Bis(4-bromophenyl)-1-[2,3,7,8-tetrakis(4-bromophenyl)benzo[de ]chromen-9-yl]isoquinoline (3ah)
Purified by column chromatography (hexane/EtOAc 10:1); yellow solid; yield: 170 mg (69%); mp 203–205 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.42–6.50 (m, 2 H), 6.50–6.56 (m, 2 H), 6.82–6.92 (m, 4 H), 6.96–7.00 (m, 3 H), 7.07–7.08 (m, 3 H), 7.13–7.24 (m, 5 H), 7.27–7.30 (m, 2 H), 7.38–7.41 (m, 1 H), 7.41–7.45 (m, 2 H), 7.51–7.60 (m, 6 H), 8.13 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 116.9, 116.9, 118.3, 120.4, 121.1, 121.6, 121.7, 121.9, 122.2, 122.8, 123.3, 125.8, 127.2, 127.3, 128.6, 128.8, 129.9, 130.1, 130.4, 130.7, 130.9, 131.2, 131.5, 131.5, 131.7, 132.0, 132.34, 132.7, 132.7, 132.9, 132.9, 133.0, 133.0, 133.3, 133.7, 133.9, 135.7, 135.7, 137.4, 138.2, 139.4, 139.4, 148.0, 148.8, 149.6, 156.7.
HRMS (APCI): m /z [M + H]+ calcd for C57 H32 Br6 NO: 1225.7529; found: 1225.7500.
3,4-Dipropyl-1-(2,3,7,8-tetrapropylbenzo[de ]chromen-9-yl)isoquinoline (3ai)
3,4-Dipropyl-1-(2,3,7,8-tetrapropylbenzo[de ]chromen-9-yl)isoquinoline (3ai)
Purified by column chromatography (hexane/EtOAc 40:1); yellow oil; yield: 69 mg (63%).
1 H NMR (400 MHz, CDCl3 ): δ = 0.43 (t, J = 7.3 Hz, 3 H), 0.61 (t, J = 7.3 Hz, 3 H), 0.76–0.87 (m, 2 H), 0.94 (t, J = 7.3 Hz, 3 H), 1.01 (t, J = 7.3 Hz, 3 H), 1.08–1.13 (m, 6 H), 1.21–1.27 (m, 1 H), 1.47–1.54 (m, 3 H), 1.65–1.87 (m, 6 H), 1.95 (t, J = 7.2 Hz, 2 H), 2.12–2.19 (m, 1 H), 2.28–2.32 (m, 2 H), 2.59–2.66 (m, 1 H), 2.89–2.91 (m, 2 H), 2.92–3.14 (m, 4 H), 6.75 (d, J = 7.2 Hz, 1 H), 7.29–7.35 (m, 2 H), 7.49 (d, J = 8.7 Hz, 1 H), 7.56–7.65 (m, 2 H), 8.02 (d, J = 8.6 Hz, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 13.3, 14.2, 14.4, 14.7, 14.8, 19.6, 21.2, 23.5, 23.8, 24.3, 24.4, 28.4, 29.8, 30.7, 31.6, 33.2, 37.4, 111.2, 111.6, 118.6, 119.4, 121.5, 123.1, 125.2, 126.7, 127.1, 127.4, 127.6, 128.0, 129.3, 131.5, 133.3, 135.6, 138.4, 148.3, 151.7, 152.4, 156.2.
HRMS (APCI): m /z [M + H]+ calcd for C39 H50 NO: 548.3887; found: 548.3867.
1-(5-Methyl-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3ba)
1-(5-Methyl-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3ba)
Purified by column chromatography (hexane/EtOAc 3:1); yellow solid; yield: 114 mg (75%); mp 159–161 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 2.19 (s, 3 H), 6.39 (s, 1 H), 6.68–6.70 (m, 4 H), 6.79–6.88 (m, 4 H), 6.99–7.02 (m, 3 H), 7.10 (s, 5 H), 7.16–7.21 (m, 4 H), 7.23 (m, 2 H), 7.247.30 (m, 4 H), 7.33–7.42 (m, 5 H), 7.48–7.52 (m, 2 H), 7.55–7.57 (m, 1 H), 8.16–8.18 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 22.4, 117.3, 117.9, 118.3, 120.2, 122.2, 125.6, 125.7, 126.3, 126.5, 126.7, 127.1, 127.2, 127.4, 127.4, 127.6, 127.7, 127.8, 128.0, 128.4, 128.6, 129.3, 129.3, 129.7, 130.0, 130.3, 130.4, 130.9, 131.1, 131.2, 131.5, 131.6, 131.7, 131.8, 132.2, 133.8, 134.2, 135.7, 136.0, 137.6, 138.2, 139.3, 139.9, 140.8, 141.2, 148.8, 149.7, 149.9, 157.1.
HRMS (APCI): m /z [M + H]+ calcd for C58 H40 NO: 766.3104; found: 766.3101.
1-(5-tert -Butyl-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3ca)
1-(5-tert -Butyl-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3ca)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 122 mg (76%); mp 238–240 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 1.11 (s, 9 H), 6.65–6.71 (m, 5 H), 6.80–6.89 (m, 4 H), 6.99–7.03 (m, 2 H), 7.07–7.12 (m, 5 H), 7.16–7.32 (m, 10 H), 7.32–7.43 (m, 5 H), 7.46–7.53 (m, 2 H), 7.55–7.58 (m, 1 H), 8.15–8.17 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 30.9, 35.1, 115.2, 117.6, 118.0, 118.4, 120.1, 125.6, 125.7, 126.3, 126.4, 126.7, 127.1, 127.2, 127.3, 127.4, 127.6, 127.8, 127.8, 127.9, 128.4, 128.6, 129.2, 129.3, 129.7, 130.1, 130.3, 130.9, 131.1, 131.2, 131.4, 131.6, 131.6, 131.9, 133.9, 135.7, 136.0, 137.6, 139.3, 139.9, 140.7, 141.1, 148.5, 149.6, 149.8, 151.0, 157.1.
HRMS (APCI): m /z [M + H]+ calcd for C61 H46 NO: 808.3574; found: 808.3583.
1-(5-Methoxy-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3da)
1-(5-Methoxy-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3da)
Purified by column chromatography (hexane/EtOAc 5:1); yellow solid; yield: 126 mg (80%); mp 155–157 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 3.59 (s, 3 H), 6.23 (d, J = 2.2 Hz, 1 H), 6.56 (d, J = 2.2 Hz, 1 H), 6.68–6.73 (m, 4 H), 6.80–6.89 (m, 4 H), 6.98–7.05 (m, 3 H), 7.10 (s, 5 H), 7.18–7.23 (m, 6 H), 7.27–7.40 (m, 7 H), 7.46–7.52 (m, 2 H), 7.55–7.56 (m, 1 H), 8.15–8.18 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 54.9, 101.9, 108.4, 117.0, 117.5, 125.7, 125.7, 126.4, 126.4, 126.7, 127.1, 127.2, 127.4, 127.4, 127.6, 127.7, 127.8, 128.0, 128.0, 128.1, 128.4, 128.6, 129.3, 129.7, 130.0, 130.1, 130.3, 130.8, 131.0, 131.2, 131.3, 131.5, 131.8, 133.6, 134.2, 135.4, 135.6, 136.0, 137.5, 139.4, 139.9, 141.1, 141.3, 149.2, 149.6, 149.8, 157.0, 159.7.
HRMS (APCI): m /z [M + H]+ calcd for C58 H40 NO2 : 782.3054; found: 782.3045.
3,4-Diphenyl-1-[2,3,7,8-tetraphenyl-5-(trifluoromethyl)benzo[de ]chromen-9-yl]isoquinoline (3ea)
3,4-Diphenyl-1-[2,3,7,8-tetraphenyl-5-(trifluoromethyl)benzo[de ]chromen-9-yl]isoquinoline (3ea)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 138 mg (84%); mp 160–162 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.67–6.71 (m, 5 H), 6.82–6.89 (m, 4 H), 6.98–7.07 (m, 2 H), 7.09–7.13 (m, 5 H), 7.15–7.25 (m, 6 H), 7.27–7.35 (m, 3 H), 7.37–7.44 (m, 5 H), 7.50–7.55 (m, 3 H), 7.57–7.60 (m, 1 H), 8.09–8.12 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 111.4, 117.0, 120.4, 120.4, 120.9, 122.8, 122.9, 125.5, 125.9, 126.1, 126.7, 126.9, 127.0, 127.1, 127.2, 127.2, 127.4, 127.5, 127.9, 128.2, 128.2, 128.4, 128.5, 128.6, 129.6, 129.6, 129.8, 129.9, 130.0, 130.2, 130.3, 130.7, 130.9, 131.2, 131.2, 131.4, 131.5, 131.6, 132.3, 133.0, 133.2, 134.0, 134.7, 136.1, 137.4, 138.1, 139.1, 141.0, 142.1, 149.5, 149.9, 150.0, 156.2.
19 F NMR (376 MHz, CDCl3 ): δ = –63.03.
HRMS (APCI): m /z [M + H]+ calcd for C58 H37 F3 NO: 820.2822; found: 820.2848.
1-(5-Bromo-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3fa)
1-(5-Bromo-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3fa)
Purified by column chromatography (hexane/EtOAc 4:1) and GPC; yellow solid; yield: 110 mg (67%); mp 172–174 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.61 (m, 1 H), 6.68–6.70 (m, 4 H), 6.80–6.89 (m, 4 H), 6.98–7.05 (m, 2 H), 7.10 (s, 5 H), 7.12–7.31 (m, 9 H), 7.32–7.43 (m, 6 H), 7.49–7.53 (m, 2 H), 7.55–7.58 (m, 1 H), 8.10–8.13 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 116.5, 119.2, 119.3, 120.4, 123.6, 124.9, 125.8, 125.9, 126.6, 126.7, 126.8, 128.0, 128.2, 128.4, 128.6, 129.5, 129.5, 129.6, 129.8, 130.2, 130.5, 130.7, 130.9, 131.1, 131.3, 131.5, 133.3, 134.5, 134.8, 135.0, 136.1, 137.4, 138.4, 139.3, 141.0, 141.9, 149.7, 149.9, 149.9, 156.5.
HRMS (APCI): m /z [M + H]+ calcd for C57 H37 BrNO: 832.2037; found: 832.1912.
1-(4-Methyl-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3ga)
1-(4-Methyl-2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-3,4-diphenylisoquinoline (3ga)
Purified by column chromatography (hexane/EtOAc 5:1); yellow solid; yield: 47 mg (30%); crystals suitable for X-ray measurement were obtained from CH2 Cl2 solution layered with pentane; mp 157–159 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 1.62 (s, 3 H), 6.65–6.71 (m, 4 H), 6.79–6.86 (m, 4 H), 6.95–7.01 (m, 5 H), 7.05–7.11 (m, 4 H), 7.15–7.41 (m, 14 H), 7.48–7.54 (m, 3 H), 8.15–8.17 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 22.6, 117.7, 118.7, 123.1, 123.5, 125.6, 125.7, 126.2, 126.3, 126.4, 126.5, 126.6, 127.0, 127.0, 127.2, 127.3, 127.4, 127.6, 127.7, 127.8, 127.9, 128.3, 128.8, 129.2, 129.6, 130.0, 130.3, 130.9, 131.2, 131.5, 131.5, 131.7, 132.0, 132.9, 134.4, 135.9, 137.6, 138.5, 139.3, 139.6, 139.7, 141.1, 149.6, 149.7, 150.2, 157.2.
HRMS (APCI): m /z [M + H]+ calcd for C58 H40 NO: 766.3104; found: 766.3120.
3,4-Diphenyl-1-(2,3,6,7-tetraphenylthieno[4,3,2-de ]chromen-8-yl)isoquinoline (3ha)
3,4-Diphenyl-1-(2,3,6,7-tetraphenylthieno[4,3,2-de ]chromen-8-yl)isoquinoline (3ha)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 35 mg (23%); crystals suitable for X-ray measurement were obtained from CH2 Cl2 solution layered with pentane; mp 164–166 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.39 (m, 1 H), 6.72 (m, 2 H), 6.86–6.94 (m, 6 H), 6.99–7.11 (m, 7 H), 7.16–7.35 (m, 12 H), 7.39–7.42 (m, 2 H), 7.51–7.55 (m, 2 H), 7.56–7.60 (m, 1 H), 8.17–8.19 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 111.2, 115.9, 119.7, 125.8, 126.0, 126.5, 126.7, 126.8, 127.0, 127.1, 127.3, 127.3, 127.4, 127.6, 127.8, 128.2, 128.3, 128.4, 128.9, 129.1, 129.6, 129.7, 129.8, 130.1, 130.1, 131.20, 131.5, 133.6, 135.9, 136.0, 137.5, 139.3, 139.5, 140.3, 140.0, 142.1, 148.5, 149.7, 149.9, 155.9.
HRMS (APCI): m /z [M + H]+ calcd for C55 H36 NOS: 758.2512; found: 758.2511.
6-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3ia)
6-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3ia)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 129 mg (84%); mp 157–159 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 2.39 (s, 3 H), 6.53–6.55 (m, 1 H), 6.70–6.73 (m, 4 H), 6.81–6.88 (m, 4 H), 6.99–7.05 (m, 2 H), 7.07–7.11 (m, 5 H), 7.13–7.32 (m, 12 H), 7.33–7.43 (m, 6 H), 8.04–8.06 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 22.2, 116.3, 117.4, 118.9, 121.9, 123.1, 124.6, 125.7, 125.8, 126.4, 126.6, 127.0, 127.2, 127.4, 127.4, 127.7, 127.8, 127.9, 128.0, 128.1, 128.2, 128.4, 128.6, 128.8, 129.0, 129.3, 129.4, 130.0, 130.1, 130.3, 130.9, 131.0, 131.1, 131.2, 131.4, 131.6, 131.8, 132.4, 133.7, 133.8, 135.7, 136.3, 137.7, 139.2, 139.7, 140.0, 140.7, 141.3, 148.6, 149.7, 150.1, 156.6.
HRMS (APCI): m /z [M + H]+ calcd for C58 H40 NO: 766.3104; found: 766.3104.
6-Methoxy-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3ja)
6-Methoxy-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3ja)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 122 mg (78%); mp 157–159 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 3.68 (s, 3 H), 6.52–6.54 (m, 1 H), 6.71–6.85 (m, 6 H), 6.87–6.91 (m, 3 H), 6.97–7.05 (m, 2 H), 7.09–7.16 (m, 8 H), 7.17–7.32 (m, 9 H), 7.34–7.41 (m, 5 H), 8.02–8.04 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 55.2, 103.9, 116.3, 117.4, 118.8, 121.9, 123.0, 123.2, 125.7, 126.4, 126.5, 126.6, 127.0, 127.2, 127.4, 127.7, 127.8, 127.9, 128.0, 128.0, 128.2, 128.5, 128.6, 128.8, 129.2, 129.4, 129.4, 130.1, 130.2, 130.9, 131.0, 131.2, 131.3, 131.4, 131.6, 131.7, 132.3, 133.7, 133.8, 135.7, 133.7, 133.8, 135.7, 137.8, 138.1, 139.2, 139.7, 140.6, 141.4, 148.6, 149.7, 150.6, 156.1, 160.4.
HRMS (APCI): m /z [M + H]+ calcd for C58 H40 NO2 : 782.3054; found: 782.3053.
3,4-Diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-6-(trifluoromethyl)isoquinoline (3ka)
3,4-Diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)-6-(trifluoromethyl)isoquinoline (3ka)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 83 mg (56%); mp 188–190 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.57–6.58 (m, 1 H), 6.68–6.70 (m, 4 H), 6.83–6.90 (m, 4 H), 7.00–7.02 (m, 2 H), 7.09–7.14 (m, 5 H), 7.16–7.26 (m, 10 H), 7.32–7.44 (m, 6 H), 7.68 (d, J = 8.8 Hz, 1 H), 7.89 (s, 1 H), 8.32 (d, J = 8.7 Hz, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 116.6, 117.6, 117.9, 121.8, 122.1, 123.2, 123.6, 123.6, 125.2, 125.9, 126.5, 127.1, 127.3, 127.5, 127.7, 127.8, 128.0, 128.0, 128.1, 128.2, 128.4, 128.5, 128.7, 129.0, 129.3, 130.0, 130.2, 130.9, 131.0, 131.1, 131.3, 131.3, 131.3, 131.5, 131.5, 131.8, 132.3, 133.6, 134.1, 135.3, 135.4, 136.3, 138.9, 139.5, 140.5, 148.7, 149.9, 151.4, 157.2.
19 F NMR (376 MHz, CDCl3 ): δ = –62.78.
HRMS (APCI): m /z [M + H]+ calcd for C58 H37 F3 NO: 820.2822; found: 820.2815.
7-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3la)
7-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3la)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 135 mg (88%); mp 158–160 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 2.47 (s, 3 H), 6.55 (d, J = 7.1 Hz, 1 H), 6.69–6.76 (m, 4 H), 6.79–6.83 (m, 1 H), 6.84–6.90 (m, 3 H), 6.95–7.04 (m, 3 H), 7.11–7.12 (m, 5 H), 7.14–7.31 (m, 10 H), 7.33–7.41 (m, 6 H), 7.44–7.46 (m, 1 H), 7.88 (s, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 21.8, 116.3, 117.4, 119.0, 121.9, 123.1, 125.6, 125.7, 126.2, 126.4, 126.5, 126.6, 127.0, 127.3, 127.4, 127.4, 127.7, 127.8, 127.9, 128.0, 128.1, 128.2, 128.3, 128.5, 129.3, 129.4, 130.1, 130.3, 130.9, 131.0, 131.1, 131.2, 131.4, 131.5, 131.6, 131.9, 132.5, 133.8, 133.8, 134.3, 135.7, 136.3, 137.7, 139.2, 139.8, 140.8, 141.3, 148.7, 149.2, 149.8, 156.1.
HRMS (APCI): m /z [M + H]+ calcd for C58 H40 NO: 766.3104; found: 766.3102.
8-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3ma)
8-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline (3ma)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 135 mg (88%); crystals suitable for X-ray measurement were obtained by slow evaporation of hexane solution; mp 157–159 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 2.59 (s, 3 H), 6.53 (dd, J = 1.0, 7.0 Hz, 1 H), 6.67 (s, 1 H), 6.76–6.81 (m, 4 H), 6.86–6.95 (m, 4 H), 7.01–7.06 (m, 2 H), 7.10–7.20 (m, 11 H), 7.22–7.31 (m, 6 H), 7.33–7.38 (m, 5 H), 7.42–7.45 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 23.8, 116.3, 117.4, 122.0, 123.1, 123.4, 124.7, 125.6, 126.4, 126.7, 127.0, 127.3, 127.4, 127.6, 127.7, 127.7, 127.8, 128.0, 128.1, 128.3, 128.6, 129.0, 129.1, 129.5, 129.7, 129.8, 130.1, 130.9, 131.0, 131.2, 131.4, 131.5, 131.6, 132.4, 133.7, 133.8, 135.5, 135.6, 137.6, 138.1, 139.2, 139.4, 139.8, 141.1, 148.7, 148.8, 148.8, 155.2.
HRMS (APCI): m /z [M + H]+ calcd for C58 H40 NO: 766.3104; found: 766.3105.
4,5-Diphenyl-7-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)thieno[2,3-c ]pyridine (3na)
4,5-Diphenyl-7-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)thieno[2,3-c ]pyridine (3na)
Purified by column chromatography (hexane/EtOAc 4:1); yellow solid; yield: 43 mg (28%); mp 172–174 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.55 (dd, J = 1.4, 6.7 Hz, 1 H), 6.76–6.77 (m, 1 H), 6.82–6.84 (m, 1 H), 6.86–6.95 (m, 5 H), 7.00–7.08 (m, 2 H), 7.10–7.20 (m, 11 H), 7.22–7.24 (m, 8 H), 7.33–7.45 (m, 4 H), 7.54 (d, J = 5.5 Hz, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 116.4, 117.5, 118.9, 121.9, 123.1, 123.5, 125.9, 126.4, 126.8, 127.1, 127.3, 127.5, 127.7, 127.9, 127.9, 128.1, 128.2, 128.4, 128.5, 128.7, 129.3, 130.4, 130.6, 131.0, 131.1, 131.4, 131.5, 131.5, 132.5, 133.7, 134.0, 135.6, 136.6, 138.2, 139.1, 139.4, 140.1, 140.6, 145.6, 148.7, 149.8, 150.1, 150.9.
HRMS (APCI): m /z [M + H]+ calcd for C55 H36 NOS: 758.2512; found: 758.2511.
6-(3,4-Diphenylisoquinolin-1-yl)-4,5-diphenylbenzo[b ]thiophen-7-ol (4oa)
6-(3,4-Diphenylisoquinolin-1-yl)-4,5-diphenylbenzo[b ]thiophen-7-ol (4oa)
Purified by column chromatography (hexane/EtOAc 5:1) and GPC; yellow solid; yield: 54 mg (50%); crystals suitable for X-ray measurement were obtained by slow evaporation of CHCl3 solution; mp 152–154 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.49–6.57 (m, 2 H), 6.66–6.78 (m, 1 H), 6.79–7.10 (m, 8 H), 7.11–7.18 (m, 5 H), 7.29–7.47 (m, 8 H), 7.71 (d, J = 8.4 Hz, 1 H), 9.90 (br, 1 H) °C.
13 C NMR (100 MHz, CDCl3 ): δ = 119.5, 124.7, 125.1, 125.5, 126.1, 126.3, 126.5, 126.9, 127.3, 127.3, 127.4, 127.5, 127.78, 128.1, 128.5, 129.3, 130.0, 130.1, 130.3, 130.9, 131.3, 132.3, 136.3, 137.0, 138.3, 139.1, 134.0, 140.0, 141.1, 148.6, 149.3, 157.8.
HRMS (APCI): m /z [M + H]+ calcd for C41 H28 NOS: 582.1886; found: 582.1897.
2-(3,4-Diphenylisoquinolin-1-yl)-8-methyl-3,4-diphenylnaphthalen-1-ol (4pa)
2-(3,4-Diphenylisoquinolin-1-yl)-8-methyl-3,4-diphenylnaphthalen-1-ol (4pa)
Purified by column chromatography (hexane/EtOAc 10:1) and GPC; yellow solid; yield: 86 mg (73%); crystals suitable for X-ray measurement were obtained by hexane vapor diffusion into EtOAc solution; mp 170–172 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 3.04 (s, 3 H), 6.58–6.65 (m, 2 H), 6.73–6.78 (m, 2 H), 6.84 (d, J = 7.7 Hz, 2 H), 7.03–7.10 (m, 2 H), 7.17–7.23 (m, 4 H), 7.24–7.30 (m, 2 H), 7.30–7.42 (m, 8 H), 7.43–7.46 (m, 1 H), 7.48–7.50 (m, 1 H), 7.59–7.61 (m, 1 H), 7.84–7.86 (m, 1 H), 8.76 (br, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 25.4, 118.8, 124.0, 125.2, 125.3, 125.5, 126.2, 126.3, 126.5, 126., 127.1, 127.3, 127.4, 127.7, 127.9, 128.1, 128.5, 130.2, 130.3, 130.4, 131.2, 131.5, 131.6, 132.3, 135.6, 136.3, 136.7, 137.1, 138.3, 140.0, 140.1, 140.3, 148.8, 153.2, 158.2.
HRMS (APCI): m /z [M + H]+ calcd for C44 H32 NO: 590.2478; found: 590.2494.
3,4-Diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline Hydrochloride (3aa·HCl)
3,4-Diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinoline Hydrochloride (3aa·HCl)
To a solution of 3aa (0.1 mmol) in CH2 Cl2 (1.0 mL) was added HCl solution (1 mol/L in Et2 O, 1.0 mL) at r.t. After stirring for 1 h, volatiles were removed under reduced pressure to give isoquinolinium salt 3aa ·HCl as a red solid; yield: 74 mg (93%); mp 187–189 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 6.58–6.59 (m, 1 H), 6.67–6.90 (m, 8 H), 7.01–7.08 (m, 3 H), 7.08–7.42 (m, 22 H), 7.61 (br, 3 H), 8.26 (br, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 116.7, 117.7, 121.8, 123.3, 126.0, 126.5, 126.6, 127.3, 127.5, 127.8, 127.8, 127.9, 128.1, 128.2, 128.5, 128.7, 129.2, 129.4, 129.9, 130.1, 130.6, 130.8, 131.0, 131.1, 131.2, 131.3, 131.8, 132.1, 132.4, 133.7, 134.4, 135.4, 138.9, 139.4, 140.4, 148.8, 150.1.
HRMS (APCI): m /z [M – Cl]+ calcd for C57 H38 NO: 752.2948; found: 752.2925.
2-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinolinium Triflate (3aa·MeOTf)
2-Methyl-3,4-diphenyl-1-(2,3,7,8-tetraphenylbenzo[de ]chromen-9-yl)isoquinolinium Triflate (3aa·MeOTf)
To a solution of 3aa (0.1 mmol) in CH2 Cl2 (1.0 mL) was added MeOTf solution (0.10 mmol in 0.5 mL of CH2 Cl2 ) at r.t. After stirring for 1 h, volatiles were removed under reduced pressure to give isoquinolinium salt 3aa ·MeOTf as a red solid; yield: 78 mg (85%); mp 181–183 °C.
1 H NMR (400 MHz, CDCl3 ): δ = 3.98 (s, 3 H), 6.49–6.56 (m, 2 H), 6.71–6.85 (m, 5 H), 6.92–7.10 (m, 6 H), 6.94–7.24 (m, 8 H), 7.28–7.42 (m, 10 H), 7.42–7.54 (m, 2 H), 7.70–7.72 (m, 1 H), 8.10–8.14 (m, 2 H), 8.50–8.52 (m, 1 H).
13 C NMR (100 MHz, CDCl3 ): δ = 46.6, 108.3, 118.8, 118.9, 119.3, 121.4, 122.5, 124.1, 127.3, 127.4, 127.7, 127.9, 128.3, 128.37, 128.40, 128.5, 128.8, 129.0, 129.1, 129.2, 129.2, 129.3, 129.3, 129.6, 129.86, 129.91, 130.1, 130.4, 130.5, 130.86, 130.94, 131.1, 131.3, 132.1, 132.3, 132.5, 132.7, 133.4, 134.0, 136.0, 136.8, 137.2, 137.29, 137.4, 137.8, 138.9, 145.3, 150.0, 157.8.
HRMS (APCI): m /z [M – MeOTf + H]+ calcd for C57 H38 NO: 752.2948; found: 752.2935.
